David A. Siegel Mustang Bio, Inc. Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.35 - $0.72 $1,050 - $2,160	-3,000 Reduced 5.24%	54,200 $20,000
Q4 2022 Feb 14, 2023	SELL	$0.32 - $8.27 $46,496 - $1.2 Million	-145,300 Reduced 71.75%	57,200 $22,000
Q3 2022 Nov 14, 2022	SELL	$0.46 - $7.2 $69,138 - $1.08 Million	-150,300 Reduced 42.6%	202,500 $95,000
Q2 2022 Aug 15, 2022	SELL	$0.58 - $1.13 $108,053 - $210,518	-186,300 Reduced 34.56%	352,800 $206,000
Q1 2022 May 16, 2022	SELL	$0.73 - $1.81 $203,378 - $504,266	-278,600 Reduced 34.07%	539,100 $544,000
Q4 2021 Feb 14, 2022	SELL	$1.66 - $2.64 $693,050 - $1.1 Million	-417,500 Reduced 33.8%	817,700 $1.36 Million
Q3 2021 Nov 15, 2021	SELL	$2.58 - $3.36 $504,648 - $657,216	-195,600 Reduced 13.67%	1,235,200 $3.32 Million
Q2 2021 Aug 16, 2021	BUY	$2.7 - $3.81 $2.2 Million - $3.1 Million	813,100 Added 131.63%	1,430,800 $4.75 Million
Q1 2021 May 17, 2021	BUY	$3.02 - $5.16 $1.02 Million - $1.74 Million	336,800 Added 119.9%	617,700 $2.05 Million
Q4 2020 Feb 16, 2021	SELL	$2.66 - $4.18 $546,896 - $859,407	-205,600 Reduced 42.26%	280,900 $1.06 Million
Q3 2020 Nov 16, 2020	BUY	$3.01 - $3.88 $1.46 Million - $1.89 Million	486,500 New	486,500 $1.53 Million

415K

Ticker MBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,222,000
Market Cap $23.1M
Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.